Novel use of an established agent: Topotecan is anti-angiogenic in experimental wilms tumor

Journal of Pediatric Surgery

Volumn 36, Issue 12, 2001, Pages 1781-1784

  Soffer, Samuel Z ^a   Kim, Eugene ^a   Moore, James T ^a   Huang, Jianzhong ^a   Yokoi, Akiko ^a   Manley, Christina ^a   O'Toole, Kathleen ^a   Middlesworth, William ^a   Stolar, Charles ^a   Yamashiro, Darrell ^a   Kandel, Jessica ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Angiogenesis; Topotecan; Wilms tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; FLUORESCEIN; TOPOTECAN;

ANGIOGENESIS; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; MOUSE; NEPHROBLASTOMA; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 0035206188     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2001.28823     Document Type: Article

References (9)

1. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms tumor
2. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
3. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer
4. Tumor resistance to alkylating agents conferred by mechanism operative only in vivo
5. Camptothecins: A review of their development and schedules of administration
6. Topotecan in pediatric patients and progressive solid tumors: A Pediatric Oncology Group phase II study
7. Anti-angiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT- 11 studied in the mouse cornea model
8. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia
9. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance